Definity, Optison(perflutren)
Definity, Luminity, Optison (perflutren) is a small molecule pharmaceutical. Perflutren was first approved as Optison on 1998-05-17. It has been approved in Europe to treat echocardiography.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Definity rt
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Perflutren
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEFINITY | Lantheus Medical Imaging | N-021064 RX | 2001-07-31 | 1 products, RLD, RS |
| DEFINITY RT | Lantheus Medical Imaging | N-021064 RX | 2020-11-17 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| definity | New Drug Application | 2024-03-13 |
| definity rt | New Drug Application | 2024-03-13 |
| optison | New Drug Application | 2025-08-25 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| Q9957 | Injection, perflutren lipid microspheres, per ml |
Clinical
Clinical Trials
174 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | 2 | 1 | 5 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | 3 | 4 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | 2 | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | 1 | 2 |
| Coronary disease | D003327 | — | — | — | — | — | 1 | — | 1 |
| Pulmonary heart disease | D011660 | — | I27.81 | — | — | — | 1 | — | 1 |
| Stroke volume | D013318 | — | — | — | — | — | 1 | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | — | 1 |
| Myocardial perfusion imaging | D055414 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 1 | 1 | — | — | 2 |
| Compartment syndromes | D003161 | — | T79.A0 | — | 1 | 1 | — | — | 1 |
| Chronic exertional compartment syndrome | D000083182 | — | — | — | 1 | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | — | 1 |
| Therapeutic chemoembolization | D016461 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | — | N18 | — | 2 | — | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | — | — | — | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
| Von hippel-lindau disease | D006623 | — | Q85.83 | — | 1 | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
| Cystic kidney diseases | D052177 | EFO_0008615 | Q61 | — | 1 | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | — | — | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | — | 1 | — | — | — | 1 |
| Cardiac catheterization | D006328 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 2 | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 2 | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 1 | 1 |
| Atherosclerotic plaque | D058226 | HP_0031678 | I70 | — | — | — | — | 1 | 1 |
| Calcinosis | D002114 | — | — | — | — | — | — | 1 | 1 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | — | — | 1 | 1 |
| Pathologic neovascularization | D009389 | — | — | — | — | — | — | 1 | 1 |
| Aneurysm | D000783 | — | I72.9 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Perflutren |
| INN | perflutren |
| Description | Octafluoropropane is a fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines. It is a fluorocarbon and a fluoroalkane. It derives from a hydride of a propane. |
| Classification | Small molecule |
| Drug class | blood substitutes and/or diagnostics (perfluorochemicals) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | FC(F)(F)C(F)(F)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 76-19-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1663 |
| ChEBI ID | 31980 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | CK0N3WH0SR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,578 documents
View more details
Safety
Black-box Warning
Black-box warning for: Definity, Definity rt, Optison
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,388 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use